Projet Ra&D à l'Ecole d'Ingénieurs et d'Architectes de Fribourg Développement d'un Nouvel Agent Anti-SIDA: NU 1320
FH - HES
Keywords:Aids treatment, Nonnucleoside inhibitor, Nu 1320, Scale-up
AbstractThe division of chemistry at the School of Engineering and Architecture of Fribourg is involved with the School of Engineering of Geneva in the development of a new drug for the treatment of AIDS. This recently discovered molecule, called NU 1320, has already shown a powerful antiviral activity. NU 1320 is a nonnucleoside inhibitor, which stops the formation of the retrotranscription complexe of the HIV-virus. The concentration of NU 1320 to inhibit 50% of viral replication is 10–6 nM: such a low concentration and the non-toxicity will prevent the occurrence of side effects for the patient. As a future potential HIV drug, the University of Applied Sciences of Western Switzerland (HES-SO) has invested in this research with the start of a project for the scale-up of this new antiviral molecule with the intention to perform in vivo tests.
How to Cite
M. Poffet, J.-M. Bourgeois, Chimia 2004, 58, 62, DOI: 10.2533/000942904777678370.
Columns, Conference Reports
Copyright (c) 2004 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.